Serina Therapeutics grants 30,500 options to director

Serina Therapeutics, Inc. reported that director Simon Farrell received a grant of stock options covering 30,500 shares of common stock.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that director Simon Farrell received a grant of stock options covering 30,500 shares of common stock. The options have an exercise price of $2.1700 per share, expire on 2036-07-22, and vest in substantially equal yearly installments over three years beginning on the first anniversary of the grant date, subject to his continued service. Following this grant, Farrell holds 30,500 stock options directly.

Insider Trade Summary

Grant/Award: 30,500 shares

Grant/Award 1 txn

Insider Simon Farrell

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	30,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,500 contracts (Direct)

Footnotes (1)

1. F1. The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Key Figures

Stock options granted: 30,500 options Exercise price: $2.1700 per share Underlying common shares: 30,500 shares +2 more

5 metrics

Stock options granted 30,500 options Grant to director Simon Farrell on 2026-07-22

Exercise price $2.1700 per share Exercise price of the reported stock option grant

Underlying common shares 30,500 shares Common Stock underlying the granted stock options

Options expiration date 2036-07-22 Expiration date of the granted stock options

Vesting period 3 years Options fully vested on the third anniversary of the grant date

Key Terms

Stock Option (right to buy), exercise price, vesting, underlying security

4 terms

Stock Option (right to buy) financial

"Security title reported as Stock Option (right to buy)"

exercise price financial

"Conversion or exercise price reported as 2.1700 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock options vest in substantially equal yearly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"Underlying security title identified as Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Serina Therapeutics (SER) report for director Simon Farrell?

Serina Therapeutics reported a grant of 30,500 stock options to director Simon Farrell. The options let him buy common shares at $2.17 each, expiring on July 22, 2036, and vest in equal annual installments over three years of continued service.

What is the exercise price of Simon Farrell’s new options at Serina Therapeutics (SER)?

The granted stock options have an exercise price of $2.1700 per share. This is the fixed price at which Farrell may purchase Serina Therapeutics common stock upon exercise of the options, subject to the vesting schedule and other grant conditions.

How do the 30,500 Serina Therapeutics (SER) stock options granted to Simon Farrell vest?

The 30,500 stock options vest in substantially equal yearly installments. Vesting starts on the first anniversary of the grant date and the options become fully vested on the third anniversary, contingent on Farrell’s continued service with Serina Therapeutics.

When do Simon Farrell’s Serina Therapeutics (SER) stock options expire?

The stock options granted to Simon Farrell expire on July 22, 2036. After that expiration date, any unexercised options will lapse, meaning they can no longer be used to purchase Serina Therapeutics common stock under this grant.

Did Simon Farrell buy or sell any Serina Therapeutics (SER) shares in this Form 4?

No open-market buy or sell is reported; it is a grant of stock options. Farrell acquired derivative securities as compensation, giving him the right to purchase common shares later, rather than reporting an immediate purchase or sale of stock.

What are Simon Farrell’s reported option holdings in Serina Therapeutics (SER) after this grant?

After the reported transaction, Simon Farrell directly holds 30,500 stock options. These options relate to an equal number of underlying Serina Therapeutics common shares, subject to the grant’s vesting schedule and the stated exercise price and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2026 - 06:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Farrell

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.17	07/22/2026		A		30,500		(1)	07/22/2036	Common Stock	30,500	$0	30,500	D

Explanation of Responses:

1. The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

	/s/ Steven Ledger, Attorney in Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)